Wall Street brokerages predict that Health Catalyst (NASDAQ:HCAT) will announce earnings per share of ($0.37) for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Health Catalyst’s earnings, with the highest EPS estimate coming in at ($0.34) and the lowest estimate coming in at ($0.41). The firm is scheduled to issue its next earnings report on Thursday, November 28th.

On average, analysts expect that Health Catalyst will report full year earnings of ($1.21) per share for the current year, with EPS estimates ranging from ($1.29) to ($1.15). For the next financial year, analysts forecast that the business will report earnings of ($0.96) per share, with EPS estimates ranging from ($1.05) to ($0.87). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that that provide coverage for Health Catalyst.

Health Catalyst (NASDAQ:HCAT) last issued its earnings results on Thursday, August 22nd. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.13. The company had revenue of $36.80 million during the quarter, compared to the consensus estimate of $36.44 million. The business’s quarterly revenue was up 60.1% on a year-over-year basis.

A number of brokerages recently weighed in on HCAT. Piper Jaffray Companies assumed coverage on Health Catalyst in a report on Monday, August 19th. They set an “overweight” rating and a $47.00 price objective on the stock. Svb Leerink started coverage on Health Catalyst in a research note on Monday, August 19th. They set an “outperform” rating and a $55.00 target price on the stock. Leerink Swann initiated coverage on Health Catalyst in a research note on Monday, August 19th. They set an “outperform” rating and a $55.00 target price on the stock. SunTrust Banks initiated coverage on Health Catalyst in a research report on Monday, August 19th. They set a “buy” rating and a $53.00 price target on the stock. Finally, William Blair began coverage on Health Catalyst in a research report on Monday, August 19th. They set an “outperform” rating on the stock. Eight research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and a consensus price target of $51.29.

Shares of HCAT traded up $1.29 during trading hours on Friday, reaching $35.33. 162,733 shares of the company’s stock traded hands, compared to its average volume of 342,309. Health Catalyst has a 12 month low of $32.15 and a 12 month high of $49.85.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. Its products include analytics platform, accountable care and financial, benchmarking and comparative analytics, care management and population health, clinical analytics, operations and performance management, patient safety, and services.

Further Reading: What is an economic bubble?

Get a free copy of the Zacks research report on Health Catalyst (HCAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Health Catalyst (NASDAQ:HCAT)

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.